GSE79027 L-13 3 v 6 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE79027_L-13_3_v_6_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE79027_L-13_3_v_6_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE79027_L-13_3_v_6_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE79027_L-13_3_v_6_human_up.

Results found

Linked to

 

Label

Description

 

Gene

valyl-tRNA synthetase 1

Gene

long intergenic non-protein coding RNA 3140

Gene

POU class 5 homeobox 1 pseudogene 3

Gene

long intergenic non-protein coding RNA 2688

Gene

long intergenic non-protein coding RNA 1614

Gene

GSN antisense RNA 1

Gene

VAV3 antisense RNA 1

Gene

papillary thyroid carcinoma susceptibility candidate 1

Gene

HSD11B1 antisense RNA 1

Gene

RNA, 7SL, cytoplasmic 263, pseudogene

  • Gene

    valyl-tRNA synthetase 1


  • Gene

    long intergenic non-protein coding RNA 3140


  • Gene

    POU class 5 homeobox 1 pseudogene 3


  • Gene

    long intergenic non-protein coding RNA 2688


  • Gene

    long intergenic non-protein coding RNA 1614


  • Gene

    GSN antisense RNA 1


  • Gene

    VAV3 antisense RNA 1


  • Gene

    papillary thyroid carcinoma susceptibility candidate 1


  • Gene

    HSD11B1 antisense RNA 1


  • Gene

    RNA, 7SL, cytoplasmic 263, pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.